NEW YORK — Investors who purchased shares of Rocket Pharmaceuticals, Inc. between February 27 and May 26, 2025, are being reminded of an upcoming deadline related to a class action lawsuit. The Rosen Law Firm, a prominent global investor rights law firm, has announced that August 11, 2025, is the last day to apply as a lead plaintiff in this case.
Those who bought securities of Rocket Pharmaceuticals during the specified period may be eligible for compensation without any upfront costs. Prospective participants can contact Phillip Kim, a legal representative from Rosen Law Firm, for further information about joining the class action.
A class action lawsuit has already been initiated, alleging that the defendants misled investors by providing overwhelmingly positive statements while concealing critical risks associated with their clinical trials. This includes claims that some participants experienced serious adverse events, including fatalities, linked to the company’s RP-A501 treatment protocol. The suit asserts that these misleading representations artificially inflated the stock price, leading to investor losses when the true information emerged.
Potential class members are not required to take any action to benefit from any future settlements that may arise, but those wishing to serve as lead plaintiffs must do so by the August deadline. Representing other class members, lead plaintiffs play a crucial role in guiding the litigation.
Rosen Law Firm encourages investors to select legal counsel with extensive experience in securities class actions, as many firms may not have the expertise or resources to effectively represent their interests. The firm has a history of successful outcomes, including significant settlements related to securities class actions. In 2019, Rosen Law Firm secured over $438 million for its clients.
Asking for the public’s attention, the firm emphasizes its achievements in litigation, having once achieved the largest settlement against a Chinese company in history at that time. With ongoing recognition within the legal community, Rosen Law Firm consistently ranks among the top firms for securities class action settlements.
Investors considering joining the Rocket Pharmaceuticals class action are advised to act soon, as certification of the class is pending. Until then, individuals have the option to select their counsel or remain uninvolved in the proceedings.
For updates and more information about the case, interested parties can reach out directly to legal representatives from Rosen Law Firm.
Disclaimer: This article was automatically generated by OpenAI and may contain inaccuracies. Any article can be requested for removal, retraction, or correction by contacting email contact@publiclawlibrary.org.